MAGE-A3 and MAGE-A4 specific CD4+ T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes
暂无分享,去创建一个
D. Speiser | P. Romero | P. Monnier | K. Thielemans | Jean-Paul Rivals | V. Cesson | L. Bron | V. Posevitz | D. Dojcinovic | A. Escher | Elsa Piotet | J. Rivals
[1] D. Speiser,et al. Pattern and clinical significance of cancer‐testis gene expression in head and neck squamous cell carcinoma , 2011, International journal of cancer.
[2] D. Speiser,et al. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. , 2010, Seminars in immunology.
[3] S. Jameson,et al. Positive selection optimizes the number and function of MHCII-restricted CD4+ T cell clones in the naive polyclonal repertoire , 2009, Proceedings of the National Academy of Sciences.
[4] Y. Togashi,et al. Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells , 2009, British Journal of Cancer.
[5] C. Bokemeyer,et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming , 2008, Proceedings of the National Academy of Sciences.
[6] J. Greenman,et al. Regulatory T cells: What role do they play in antitumor immunity in patients with head and neck cancer? , 2008, Head & neck.
[7] R. Longhi,et al. MAGE-A3161–175 contains an HLA-DRβ4 restricted natural epitope poorly formed through indirect presentation by dendritic cells , 2007, Cancer Immunology, Immunotherapy.
[8] Weifeng Chen,et al. Specific CD8+ T cell responses to HLA-A2 restricted MAGE-A3 p271–279 peptide in hepatocellular carcinoma patients without vaccination , 2007, Cancer Immunology, Immunotherapy.
[9] L. Bubendorf,et al. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer , 2007, International journal of cancer.
[10] M. Young,et al. Protective mechanisms of head and neck squamous cell carcinomas from immune assault , 2006, Head & neck.
[11] B. Neyns,et al. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1 , 2006, Cancer Immunology, Immunotherapy.
[12] F. Lemonnier,et al. Determination of Cellularly Processed HLA-A2402-Restricted Novel CTL Epitopes Derived from Two Cancer Germ Line Genes, MAGE-A4 and SAGE , 2005, Clinical Cancer Research.
[13] L. Old,et al. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. , 2005, Blood.
[14] Yao-Tseng Chen,et al. Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients1 , 2004, The Journal of Immunology.
[15] C. Lamers,et al. Immunologic Analysis of a Phase I/II Study of Vaccination with MAGE-3 Protein Combined with the AS02B Adjuvant in Patients with MAGE-3-Positive Tumors , 2004, Journal of immunotherapy.
[16] Yao-Tseng Chen,et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[17] Angela Bachi,et al. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. , 2003, Blood.
[18] Thierry Boon,et al. Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.
[19] F. Lemonnier,et al. Generation of CTL Recognizing an HLA-A*0201-Restricted Epitope Shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 Tumor Antigens: Implication in a Broad-Spectrum Tumor Immunotherapy1 , 2002, The Journal of Immunology.
[20] D. McNeel,et al. Identification of T helper epitopes from prostatic acid phosphatase. , 2001, Cancer research.
[21] E. Appella,et al. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. , 2001, Cancer research.
[22] D. Speiser,et al. Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma , 2000, The Journal of Immunology.
[23] R. Steinman,et al. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] D. Jäger,et al. Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma , 2000, The Journal of experimental medicine.
[25] G. Cornelis,et al. A MAGE‐A4 peptide presented by HLA‐A2 is recognized by cytolytic T lymphocytes , 1999, European journal of immunology.
[26] A. Eggermont,et al. Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes , 1999, The Journal of experimental medicine.
[27] Matteo Bellone,et al. Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11 , 1999, The Journal of experimental medicine.
[28] Lloyd J. Old,et al. A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.
[29] H. Rammensee,et al. Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ‐ELISPOT assay , 1997 .
[30] H. Rammensee,et al. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] Rika Deraemaecker,et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma , 1995, International journal of cancer.
[32] P. Guillaume,et al. Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research. , 2009, Cancer immunity.
[33] P. Haaland,et al. Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. , 2007, Journal of immunology.
[34] D. Speiser,et al. Specific T Cells by MHC Class II Tetramers Epitopes and Ex Vivo Visualization of Melanoma Patients: Identification of New Melan-A/MART-1-Specific CD4 T Cells in , 2006 .
[35] T. Whiteside,et al. p53 as an immunotherapeutic target in head and neck cancer. , 2005, Advances in oto-rhino-laryngology.
[36] S. Aamdal,et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. , 2003, European journal of cancer.
[37] B. Wollenberg,et al. Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. , 1999, Archives of otolaryngology--head & neck surgery.
[38] A. Sette,et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. , 1998, Human immunology.
[39] H. Rammensee,et al. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. , 1997, International journal of cancer.